Compare MYSZ & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | HCWB |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | Israel | United States |
| Employees | 45 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 3.0M |
| IPO Year | 2017 | 2021 |
| Metric | MYSZ | HCWB |
|---|---|---|
| Price | $0.52 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 24.3K | ★ 13.7M |
| Earning Date | 04-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.40 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $142,000.00 | ★ $4,099,750.00 |
| Revenue This Year | $41.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.50 | $0.25 |
| 52 Week High | $1.65 | $8.75 |
| Indicator | MYSZ | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 66.67 |
| Support Level | N/A | $0.37 |
| Resistance Level | $0.68 | $1.26 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 8.60 | 55.38 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.